Stock in Focus: Johnson & Johnson (JNJ)

Company Profile:

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Recent News:

On April 23, 2020, the company announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

On April 14, 2020, the company reported sales of $20.7 billion for first-quarter 2020, reflecting strong growth of 3.3%, operational growth of 4.8% and adjusted operational growth of 5.6%, inclusive of the overall estimated negative impact of the COVID-19 pandemic. EPS was $2.17 increased 56.1%; adjusted EPS was $2.30 increased 9.5%. Its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



JNJ’s strengths can be seen in its better growth and strong profitability compared with its peers. Its revenue has increased over recent several years. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, MACD is trying to cross back up and the RSI stands at 57.52 with positive bias. We rate Johnson & Johnson (JNJ) a STRONG BUY.

About the Author

has written 12932 stories on this site.

Copyright © 2012 Nine Stocks